Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens-Reference-Cited by-同舟云学术

Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens

Published:2017-10-12 Issue:5 Volume:38 Page:821-833
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Reddy K. Rajender¹,Pol Stanislas²^ORCID,Thuluvath Paul J.³,Kumada Hiromitsu⁴,Toyota Joji⁵,Chayama Kazuaki⁶,Levin James⁷,Lawitz Eric J.⁸,Gadano Adrian⁹,Ghesquiere Wayne¹⁰,Gerken Guido¹¹,Brunetto Maurizia R.¹²,Peng Cheng-Yuan¹³^ORCID,Silva Marcelo¹⁴,Strasser Simone I.¹⁵,Heo Jeong¹⁶,McPhee Fiona¹⁷,Liu Zhaohui¹⁸,Yang Rong¹⁷,Linaberry Misti¹⁹,Noviello Stephanie¹⁹

Affiliation:

1. School of Medicine; University of Pennsylvania; Philadelphia PN USA

2. Hôpital Cochin; Paris France

3. Mercy Medical Center; Baltimore MD USA

4. Toranomon Hospital; Tokyo Japan

5. Sapporo-Kosei General Hospital; Sapporo Japan

6. Hiroshima University; Hiroshima Japan

7. Dean Foundation; Madison WI USA

8. Texas Liver Institute; University of Texas Health Sciences Center; San Antonio TX USA

9. Hospital Italiano de Buenos Aires; Buenos Aires Argentina

10. Vancouver Island Health Authority; University of British Columbia; Victoria BC Canada

11. University of Duisburg-Essen; Essen Germany

12. Department of Clinical and Experimental Medicine; University of Pisa; Pisa Italy

13. School of Medicine; China Medical University; Taichung Taiwan

14. Hospital Universitario Austral; Buenos Aires Argentina

15. Royal Prince Alfred Hospital; Sydney NSW Australia

16. College of Medicine; Medical Research Institute; Pusan National University Hospital; Pusan National University; Busan Korea

17. Bristol-Myers Squibb; Wallingford CT USA

18. Bristol-Myers Squibb; Hopewell NJ USA

19. Bristol-Myers Squibb; Princeton NJ USA

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13596/fullpdf

Reference52 articles.

1. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Recommendations for testing, managing, and treating hepatitis C http://www

2. EASL recommendations on treatment of hepatitis C 2015;European Association for Study of Liver;J Hepatol,2015

3. Antiviral activity and resistance of HCV NS5A replication complex inhibitors;Gao;Curr Opin Virol,2013

4. Sustained virologic response to daclatasvir and sofosbuvir, with or without ribavirin, among patients in the french daclatasvir ATU programme infected with HCV genotypes-4, 5, and 6;Hezode;J Hepatol,2016

5. European Medicines Agency Daklinza (daclatasvir) summary of product characteristics

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study;Medicine;2024-02-16

2. The utility of HCV core antigen for evaluation of viremia at 48 weeks posttreatment with direct‐acting antivirals;Advances in Digestive Medicine;2022-04-26

3. The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysis;Liver International;2021-06-16

4. Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin;Hepatobiliary & Pancreatic Diseases International;2021-04

5. Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals;PLOS ONE;2021-02-04